share_log

康希諾生物：海外監管公告

CANSINOBIO: Overseas Regulatory Announcement

Hong Kong Stock Exchange ·  Apr 29 22:09
Summary by Futu AI
康希諾生物於2024年4月29日宣布，與上海上藥康希諾生物製藥有限公司簽署了產品轉讓與技術許可協議，涉及將重組埃博拉病毒疫苗（Ad5-EBOV）及其全球商業化權益轉讓給上藥康希諾。該交易總費用為人民幣14,417,100元，並未構成重大資產重組。上藥康師諾為康希諾生物的關聯法人，此次交易為關聯交易，已獲得董事會及監事會的批准，無需提交股東大會審議。康希諾生物表示，此次交易有利於資源合理利用，不會對公司經營產生重大不利影響，也不會影響股東利益，特別是中小股東的利益。
康希諾生物於2024年4月29日宣布，與上海上藥康希諾生物製藥有限公司簽署了產品轉讓與技術許可協議，涉及將重組埃博拉病毒疫苗（Ad5-EBOV）及其全球商業化權益轉讓給上藥康希諾。該交易總費用為人民幣14,417,100元，並未構成重大資產重組。上藥康師諾為康希諾生物的關聯法人，此次交易為關聯交易，已獲得董事會及監事會的批准，無需提交股東大會審議。康希諾生物表示，此次交易有利於資源合理利用，不會對公司經營產生重大不利影響，也不會影響股東利益，特別是中小股東的利益。
Conchino Biologics announced on 29 April 2024 that it has signed a product transfer and technical licensing agreement with Shanghai Pharmaceutical Co., Ltd., which involves the transfer of the reconstituted Ebola virus vaccine (AD5-EBOV) and its global commercialization interests to the pharmaceutical Conchino. The total cost of the transaction was RMB14,417,100 and did not constitute a major asset restructuring. The transaction is a related transaction and has been approved by the Board of Directors and the Board of Directors and the Board of Supervisors is not subject to consideration by the General Meeting. Consino Bio said that this transaction is beneficial to the fair use of resources, will not have a significant adverse effect on the company's operations and will not affect the interests of shareholders, especially those of small and medium-sized shareholders.
Conchino Biologics announced on 29 April 2024 that it has signed a product transfer and technical licensing agreement with Shanghai Pharmaceutical Co., Ltd., which involves the transfer of the reconstituted Ebola virus vaccine (AD5-EBOV) and its global commercialization interests to the pharmaceutical Conchino. The total cost of the transaction was RMB14,417,100 and did not constitute a major asset restructuring. The transaction is a related transaction and has been approved by the Board of Directors and the Board of Directors and the Board of Supervisors is not subject to consideration by the General Meeting. Consino Bio said that this transaction is beneficial to the fair use of resources, will not have a significant adverse effect on the company's operations and will not affect the interests of shareholders, especially those of small and medium-sized shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.